Evidence map›Paper›PMID 28265581›Full record

ArticleJournal of immunology research2017

Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.

Mieko Toyoda, Bong-Ha Shin, Shili Ge, James Mirocha, David Thomas, Maggie Chu, Edgar Rodriguez, Christine Chao, Anna Petrosyan, Odette A Galera and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Mieko ToyodaTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-5906-1479
Bong-Ha ShinTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Shili GeTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
James MirochaBiostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
David ThomasTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Maggie ChuTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Edgar RodriguezTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Christine ChaoTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Anna PetrosyanTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Odette A GaleraTransplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ashley VoComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jua ChoiComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alice PengComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Joseph KahwajiComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Stanley C JordanComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral infections represent significant morbidity and mortality factors in kidney transplant recipients, with CMV, EBV, and BKV infections being most common. Desensitization (DES) with IVIg and rituximab with/without plasma exchange followed by kidney transplantation with alemtuzumab induction increased successful transplant rates in HLA-sensitized patients but may represent an increased risk for viral infections due to severe lymphocyte depletion. Here, we report on the posttransplant viral infection status in 372 DES versus 538 non-DES patients. CMV and EBV viremia were significantly lower in DES patients, while BKV viremia was similar. This trend was observed primarily in CMV sero(-), EBV sero(+), and sero(-) patients. No patient developed PTLD. The incidence of BKAN, allograft, and patient survival was similar in both groups. These viral infections were not associated with subsequent allograft rejection which occurred within 6 months after the infection.

Indexed as

Cytomegalovirus InfectionsDesensitization, ImmunologicEpstein-Barr Virus InfectionsHLA AntigensKidney TransplantationAdultAgedAlemtuzumabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedBK VirusFemaleHumansImmunoglobulins, IntravenousKidneyLymphocyte DepletionAlemtuzumabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedHLA AntigensImmunoglobulins, IntravenousRituximab

Identifiers

PMID28265581
PMCPMC5317146
OpenAlexW2587734360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.